0001104659-22-047468.txt : 20220419 0001104659-22-047468.hdr.sgml : 20220419 20220419194856 ACCESSION NUMBER: 0001104659-22-047468 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220418 FILED AS OF DATE: 20220419 DATE AS OF CHANGE: 20220419 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ali Asif CENTRAL INDEX KEY: 0001921163 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37852 FILM NUMBER: 22836048 MAIL ADDRESS: STREET 1: 7707 GATEWAY BLVD., SUITE 140 CITY: NEWARK STATE: CA ZIP: 94560 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Protagonist Therapeutics, Inc CENTRAL INDEX KEY: 0001377121 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980505495 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7707 GATEWAY BLVD., SUITE 140 CITY: NEWARK STATE: CA ZIP: 94560-1160 BUSINESS PHONE: (510) 474-0170 MAIL ADDRESS: STREET 1: 7707 GATEWAY BLVD., SUITE 140 CITY: NEWARK STATE: CA ZIP: 94560-1160 FORMER COMPANY: FORMER CONFORMED NAME: Protagonist Therapeutics Inc DATE OF NAME CHANGE: 20130605 FORMER COMPANY: FORMER CONFORMED NAME: Protagonist Inc DATE OF NAME CHANGE: 20061002 4 1 tm2212815-3_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-04-18 0 0001377121 Protagonist Therapeutics, Inc PTGX 0001921163 Ali Asif C/O PROTAGONIST THERAPEUTICS, INC. 7707 GATEWAY BLVD., SUITE 140 NEWARK CA 94560-1160 0 1 0 0 Chief Financial Officer Common Stock 2022-04-18 4 A 0 13750 0.00 A 13750 D Stock Option (right to buy) 19.19 2022-04-18 4 A 0 82500 0.00 A 2032-04-18 Common Stock 82500 82500 D Represents grant of restricted stock units payable solely in shares of the Issuer's common stock that will vest in four annual installments on April 18, 2023, 2024, 2025 and 2026, subject to the Reporting Person's continued service to the Issuer. The stock option represents a right to purchase a total of 82,500 shares of the Issuer's common stock, one quarter of which will vest on April 18, 2023, with the remaining three quarters vesting in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer. /s/ Asif Ali 2022-04-19